- Home
- VERV vs LAB Comparison
VERV vs LAB Comparison
Compare VERV & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- LAB
- Stock Information
- Founded
- VERV 2018
- LAB 1999
- Country
- VERV United States
- LAB United States
- Employees
- VERV N/A
- LAB N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- VERV Health Care
- LAB Industrials
- Exchange
- VERV Nasdaq
- LAB Nasdaq
- Market Cap
- VERV 475.0M
- LAB 562.1M
- IPO Year
- VERV 2021
- LAB 2011
- Fundamental
- Price
- VERV $6.14
- LAB $1.77
- Analyst Decision
- VERV Strong Buy
- LAB Strong Buy
- Analyst Count
- VERV 4
- LAB 2
- Target Price
- VERV $25.75
- LAB $2.88
- AVG Volume (30 Days)
- VERV 1.5M
- LAB 1.7M
- Earning Date
- VERV 02-25-2025
- LAB 02-26-2025
- Dividend Yield
- VERV N/A
- LAB N/A
- EPS Growth
- VERV N/A
- LAB N/A
- EPS
- VERV N/A
- LAB N/A
- Revenue
- VERV $24,396,000.00
- LAB $155,902,000.00
- Revenue This Year
- VERV $97.47
- LAB $62.60
- Revenue Next Year
- VERV N/A
- LAB $9.19
- P/E Ratio
- VERV N/A
- LAB N/A
- Revenue Growth
- VERV 219.91
- LAB 48.23
- 52 Week Low
- VERV $4.31
- LAB $1.21
- 52 Week High
- VERV $19.34
- LAB $3.04
- Technical
- Relative Strength Index (RSI)
- VERV 53.75
- LAB 46.48
- Support Level
- VERV $5.32
- LAB $1.67
- Resistance Level
- VERV $6.87
- LAB $2.14
- Average True Range (ATR)
- VERV 0.52
- LAB 0.15
- MACD
- VERV -0.00
- LAB -0.00
- Stochastic Oscillator
- VERV 56.74
- LAB 32.73
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.